Hims & Hers Health Surges to 35th in Trading Volume with $144.4 Million in Shares Exchanged

On April 1, 2025, Hims & Hers Health (HIMS) saw a significant surge in trading volume, with a total of $144.4 million in shares exchanged, marking a 150.91% increase from the previous day. This surge placed Hims & Hers Health at the 35th position in terms of trading volume for the day. The stock price of Hims & Hers Health rose by 5.08%, marking the second consecutive day of gains, with a total increase of 6.55% over the past two days.

Hims & Hers Health's stock price experienced a notable increase after the company announced the addition of Eli Lilly's weight-loss drug Zepbound and diabetes treatment Mounjaro to its telehealth platform. This move is part of the company's strategy to expand its weight-loss offerings and provide a more comprehensive range of weight management options to its customers.

Hims & Hers Health has also added generic versions of liraglutide, a drug used for weight loss and diabetes management, to its platform. This addition is significant as it provides customers with more affordable options for weight management. However, analysts remain cautious about the financial impact of these additions, noting that the high cost of some of these drugs may limit their appeal to customers.

Despite the positive news, some analysts have expressed skepticism about the long-term financial benefits of these additions. Bank of America, for instance, maintained an Underperform rating and a $22 price target on Hims & Hers Health, citing concerns about the high cost of some of the drugs and the potential for limited customer demand. Nevertheless, the company's efforts to expand its weight management offerings are seen as a positive step towards providing a more comprehensive care experience for its customers.